Ohio is currently home to 3201 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis
NCT04562389
Recruiting
This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: USOR - Oncology Hematology Care - Kenwood, Cincinnati, Ohio
Conditions: Myelofibrosis
Register for Updates
Occupational Therapy and Registered Dietitian Services to Reduce Fall Risk Among Home Delivered Meal Clients
NCT06586970
Recruiting
The purpose of this study is to determine which of the following four service models is most effective for reducing fall risk among home-delivered meal clients: (1) meals alone, (2) meals + registered dietitian services, (3) meals + occupational therapy services, (4) meals + registered dietitian + occupational therapy services.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
02/02/2025
Locations: LifeCare Alliance, Columbus, Ohio
Conditions: Diet, Food and Nutrition, Accidental Falls, Cardiovascular Diseases, Diabetes, Debility, Frailty, Functional Disability
Register for Updates
Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Spontaneous Urticaria (CSU)
NCT06162728
Recruiting
This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled. The trial is intended to determine the safety and tolerability and assess the preliminary efficacy of briquilimab in adult participants with chronic spontaneous urticaria (CSU), who remain symptomatic despite treatment with H1 antihistamines and omalizumab. Additionally, pharmacokinetic (PK) properties of briquilimab, a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Site 103, Cincinnati, Ohio
Conditions: Chronic Spontaneous Urticaria
Register for Updates
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
NCT05873712
Recruiting
This phase II trial tests how well zanubrutinib and lisocabtagene maraleucel (liso-cel) work together in treating patients with Richter's syndrome. Richter's syndrome occurs when chronic lymphocytic leukemia and/or small lymphocytic leukemia transforms into an aggressive lymphoma, which is a cancer of the lymph nodes. Zanubrutinib is a class of medication called a kinase inhibitor. These drugs work by preventing the action of abnormal proteins that tell cancer cells to multiply, which helps stop... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Transformed
Register for Updates
Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
NCT04889430
Recruiting
The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatment naive to complement inhibitor therapy.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/31/2025
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Atypical Hemolytic Uremic Syndrome
Register for Updates
A Clinical Study of the TSX Dental Implant System (Xpresso)
NCT06571812
Recruiting
A prospective, observational, multicenter study where 62 patients needing implants in the maxilla or mandible will be enrolled. The patients will be restored with a final prosthesis no later than 4 months following implant placement surgery. The patients will come back for follow-up evaluations yearly for 2 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Ohio State University, Columbus, Ohio
Conditions: Tooth Loss
Register for Updates
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients with CLL or SLL Resistant to Covalent BTKi
NCT06466122
Recruiting
This phase II trial tests how well pirtobrutinib (LOXO-305) and venetoclax works in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that remains despite treatment (resistant) with covalent bruton tyrosine kinase inhibitors (BTKi). Pirtobrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the a protein that signals cancer cells to multiply. Venetoclax is in a class of medications called B-cell lymphoma-2 (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
Human Laboratory Study of the Effects of Nicotine Product Claims on Appeal, Perceptions, and Use Behavior
NCT06192316
Recruiting
This study evaluates knowledge, feelings and thoughts regarding nicotine products among young adults who are susceptible to but do not use tobacco/nicotine and adults who use tobacco/nicotine.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/30/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Behavior, Risk
Register for Updates
Precise Infliximab Exposure and Pharmacodynamic Control
NCT05660746
Recruiting
Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease (CD). There are limited treatment options approved for use in children and adults with Crohn's disease. Physicians need better ways to inform decisions on treatment. The main reason for this research study is to determine if a computer program that calculates an individualized dose based on a patient's blood testing results (precision dosing) can better achieve the best... Read More
Gender:
ALL
Ages:
Between 6 years and 22 years
Trial Updated:
01/30/2025
Locations: Cincinnati Children's Hospital, Cincinnati, Ohio
Conditions: Crohn Disease
Register for Updates
Keto-Brain:Investigating the Use of Ketogenic Diets in Brain Metastases
NCT05428852
Recruiting
This pilot study will be a single center, randomized controlled study of 24 participants with diagnosed BM (various primary disease sites) comparing the effect of a ketogenic (n=12) and AICR (n=12) diet. Potential participants will be identified via medical record reviews and chart reviews. Eligibility of patients will be assessed via medical record review. Randomization will be balanced by blocks of random sizes but no stratification due to the small sample size. Both groups will undergo a 16-w... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/30/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Brain Metastases, Adult
Register for Updates
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
NCT04174157
Recruiting
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. The purpose of this registry is to assess the long term outcomes of patients with SMA in the c... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/30/2025
Locations: Akron Children's Hospital, Akron, Ohio
Conditions: Spinal Muscular Atrophy (SMA)
Register for Updates
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
NCT04031677
Recruiting
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
Register for Updates